[ad_1]
Introducing the issue, Health Minister Arūnas Dulkys emphasized that Lithuania has already reserved enough vaccines and that the Janssen vaccine is not suitable for booster vaccination in the future.
“We have already booked and in 2021 Lithuania will reach almost 700 thousand. doses of this vaccine, and given the rest of the portfolio that we have requested, our needs are being satisfied, “said the minister during a government meeting.
He noted that the vaccine “is also suitable for immunity and very effective,” but not for booster vaccination in 2022-2023.
“Looking to the future, 2022-2023, the data shows that if we look at new strains, variations, variants of the virus, if we think about future revaccination, the platform of this vaccine is not suitable for that,” said the minister. .
A preliminary agreement with the pharmaceutical company Janssen Pharmaceutica NV provided for the purchase of additional doses of the vaccine against the COVID-19 disease, but the government rejected this option.
The government has already approved the purchase of the AstraZeneca vaccine: 1.86 million. dose, Janssen Pharmaceutica NV – 0.7 million. doses, Sanofi Pasteur & GSK 1.5 million doses, CureVac – 1.38 million. dose, Modern – 0.506 million. dose, BioNTech & Pfizer: 9.296 million. Novavax dose 0.633 million. dose, Valneva – 0.372 million. dose.
Some vaccines are not yet registered with the European Medicines Agency.
[ad_2]
